The glutaminase inhibitor, telaglenastat (CB-839), has been tested in combination with carfilzomib and dexamethasone in relapsed and/or refractory MM, and newer inhibitors like DRP-104 (sirpiglenastat) are in solid tumor clinical trials (184–186). Here, GLS is linked to Miyoshi myopathy.